Antiepileptic drugs in development

Lancet Neurology

Volumn 5, Issue 12, 2006, Pages 1064-1067

  Pollard, John R ^a   French, Jacqueline ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BRIVARACETAM; CLOBAZAM; ESLICARBAZEPINE; ETIRACETAM; FELBAMATE; FLUOROEFELBAMATE; GABAPENTIN; GANAXALONE; LAMOTRIGINE; LOCOSAMIDE; OXCARBAZEPINE; PREGABALIN; RETIGABINE; RUFINAMIDE; RWJ 333369; SAFINAMIDE; SELECTRACETAM; STIRIPENTOL; TALAMPANEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALROCEMIDE; VIGABATRIN; ZONISAMIDE;

APLASTIC ANEMIA; BINDING AFFINITY; CLINICAL TRIAL; CONFUSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EPILEPTOGENESIS; EVOLUTION; HUMAN; KIDNEY FAILURE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SOMNOLENCE; SPEECH DISORDER; SYNAPSE; VOMITING;

ANIMALS; ANTICONVULSANTS; DRUGS, INVESTIGATIONAL; EPILEPSY; HUMANS;

EID: 33750695268     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70627-5     Document Type: Short Survey

References (31)

1. Pellock J., Perhach J., and Felbamate Sofia R. In: Levy R., Mattson R., Meldrum B., and Perucca E. (Eds). Antiepileptic drugs. 5th edn. (2002), Lippincott Williams and Wilkins, Philadelphia 301-320
2. Rogawski M., and Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5 (2004) 553-564
3. Kwan P., and Brodie M. Early identification of refractory epilepsy. N Engl J Med 342 (2000) 314-319
4. Bialer M., Johannessen S., Kupferberg H., Levy R., Perucca E., and Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 61 (2004) 1-48
5. Rogawski M. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69 (2006) 273-294
6. Zona C., Pieri M., Klitgaard H., and Margineanu D. ucb 34714, a new pyrrolidone derivative, inhibits Na+-currents in rat cortical neurons in culture. Epilepsia 45 suppl 7 (2004) 146
7. Rolan P., Pegeolet E., and Stockis A. UCB 34714: single and multiple rising dose safety, tolerability and pharmacokinetics in healthy subjects. Epilepsia 45 suppl 7 (2004) 314
8. Leese P., Goldwater D., Hulhoven, et al. Seletracetam (UCB 44212): single and multiple rising dose safety, tolerability and pharmacokinetics in healthy subjects (abstr). http://www.aesnet.org/visitors/AnnualMeeting/Abstracts.com (accessed Oct 13, 2006)
9. Malawska B., and Kulig K. Brivaracetam UCB. Curr Opin Investig Drugs 6 (2005) 740-746
10. Hovinga C. Valrocemide (Teva/Acorda). Curr Opin Investig Drugs 5 (2004) 101-106
11. Duncan G., and Kohn H. The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res 67 (2005) 81-87
12. Lees G., Stohr T., and Errington A. Stereoselective effects of the novel anticonvulsant lacosamide against 4-AP induced epileptiform activity in rat visual cortex in vitro. Neuropharmacology 50 (2006) 98-110
13. Ben-Menachem E., Jatuzis D., Abou-Khalil B., Doty P., Rudd G., and SP667 Study Group. Efficacy and Safety of Adjunctive Oral Lacosamide for the Treatment of Partial-Onset Seizures in Patients with Epilepsy. Neurology 64 suppl 1 (2005) A187
14. Rundfeldt C., and Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett 282 (2000) 73-76
15. Rundfeldt C., and Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine: interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 50 (2000) 1063-1070
16. Schroeder B., Kubisch C., Stein V., and Jentsch T. Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy. Nature 396 (1998) 687-690
17. Tober C., Rostock A., Rundfeldt C., and Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 303 (1996) 163-169
18. Rostock A., Tober C., Rundfeldt C., et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 23 (1996) 211-223
19. Rivera-Arconada I., Martinez-Gomez J., and Lopez-Garcia J. M-current modulators alter rat spinal nociceptive transmission: an electrophysiological study in vitro. Neuropharmacology 46 (2004) 598-606
20. Blackburn-Munro G., and Jensen B. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 460 (2003) 109-116
21. Plosker G., and Scott L. Retigabine: in partial seizures. CNS Drugs 20 (2006) 601-608
22. Rufinamide: CGP 33101, E 2080, RUF 331, Xilep. Drugs R D 6 (2005) 249-252
23. Vazquez B., Maxoutova A., et al. Efficacy and safety of rufinamide as adjunctive therapy in adult patients with therapy-resistant partial-onset seizures. Epilepsia 37 suppl 7 (2000) 255
24. Glauser T., Kluger G., Sachedo R., Krauss G., Perdomo C., and Arroyo S. Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial: LBS.001. Neurology 64 (2005) 1826
25. Chappell A., Sander J., Brodie M., et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 58 (2002) 1680-1682
26. Solyom S., and Tarnawa I. Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Curr Pharm Des 8 (2002) 913-939
27. Monaghan E., Navalta L., Shum L., Ashbrook D., and Lee D. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 38 (1997) 1026-1031
28. Monaghan E., McAuley J., and Data J. Ganaxolone: a novel positive allosteric modulator of the GABA(A) receptor complex for the treatment of epilepsy. Expert Opin Investig Drugs 8 (1999) 1663-1671
29. Kerrigan J., Shields W., Nelson T., et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res 42 (2000) 133-139
30. Chiron C., Marchand M., Tran A., et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 356 (2000) 1638-1642
31. Fisher R., and Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs 16 (2002) 579-593